FDA and its European colleagues appear closer to creating guidance outlining how sponsors could use reference products licensed outside their respective regions as the basis for a biosimilar application, although it is unclear when such a document could be released.
FDA does not have anything that appears directly related to the subject on its list of guidance documents expected in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?